| 2.05 -0.03 (-1.44%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.68 | 1-year : | 3.13 |
| Resists | First : | 2.29 | Second : | 2.68 |
| Pivot price | 2.05  |
|||
| Supports | First : | 1.99 | Second : | 1.79 |
| MAs | MA(5) : | 2.12 |
MA(20) : | 2 |
| MA(100) : | 1.82 |
MA(250) : | 1.87 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.3 |
D(3) : | 59.9 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 2.48 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMRN ] has closed above bottom band by 49.5%. Bollinger Bands are 78.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.12 | 2.12 - 2.13 |
| Low: | 1.95 - 1.96 | 1.96 - 1.98 |
| Close: | 2.03 - 2.05 | 2.05 - 2.07 |
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Tue, 14 Oct 2025
Immuron Reports Strong Q1 FY26 Sales Growth Driven by Travelan® - TipRanks
Mon, 13 Oct 2025
Immuron Limited Reports Q1 Sales Growth of 34% Driven by Increased Demand for Travelan® - Quiver Quantitative
Mon, 13 Oct 2025
Immuron Q1 FY26 YoY growth - GlobeNewswire
Thu, 09 Oct 2025
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Wed, 08 Oct 2025
US$400M Potential: Immuron Submits IND for IMM-529 to FDA to treat C. difficile as oral therapy - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 264 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 57 (K) |
| Shares Short P.Month | 70 (K) |
| EPS | -0.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.02 |
| Profit Margin | -71.6 % |
| Operating Margin | -85.6 % |
| Return on Assets (ttm) | -26.1 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 29.2 % |
| Gross Profit (p.s.) | 0.71 |
| Sales Per Share | 1.08 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -3.42 |
| PEG Ratio | 0 |
| Price to Book value | 68.33 |
| Price to Sales | 1.88 |
| Price to Cash Flow | -2.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|